Guardant Health, Inc., a leading precision oncology company, announced that Blue Cross and Blue Shield of Louisiana now offers coverage for the Guardant Reveal...
Amgen announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BLINCYTO® (blinatumomab) for the treatment of...
GenomOncology announced that the GenomOncology (GO) Pathology Workbench has been selected by Personalis to support its NeXT Personal assay for molecular residual disease (MRD)...
